Morgan Stanley’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.7M | Sell |
131,645
-204,614
| -61% | -$4.2M | ﹤0.01% | 4515 |
|
|
2025
Q1 | $6.89M | Buy |
336,259
+16,242
| +5% | +$333K | ﹤0.01% | 3650 |
|
|
2024
Q4 | $7.24M | Buy |
320,017
+262,137
| +453% | +$5.93M | ﹤0.01% | 3669 |
|
|
2024
Q3 | $1.42M | Sell |
57,880
-70,757
| -55% | -$1.74M | ﹤0.01% | 4843 |
|
|
2024
Q2 | $2.97M | Buy |
128,637
+16,673
| +15% | +$385K | ﹤0.01% | 4300 |
|
|
2024
Q1 | $2.7M | Sell |
111,964
-123,894
| -53% | -$2.98M | ﹤0.01% | 4379 |
|
|
2023
Q4 | $5.43M | Buy |
235,858
+89,546
| +61% | +$2.06M | ﹤0.01% | 4329 |
|
|
2023
Q3 | $2.98M | Sell |
146,312
-38,971
| -21% | -$793K | ﹤0.01% | 4099 |
|
|
2023
Q2 | $4.33M | Buy |
185,283
+33,585
| +22% | +$784K | ﹤0.01% | 3879 |
|
|
2023
Q1 | $3.53M | Sell |
151,698
-69,977
| -32% | -$1.63M | ﹤0.01% | 4063 |
|
|
2022
Q4 | $5.58M | Buy |
221,675
+2,879
| +1% | +$72.5K | ﹤0.01% | 3654 |
|
|
2022
Q3 | $5.77M | Buy |
218,796
+57,126
| +35% | +$1.51M | ﹤0.01% | 3554 |
|
|
2022
Q2 | $4.67M | Sell |
161,670
-28,540
| -15% | -$825K | ﹤0.01% | 3831 |
|
|
2022
Q1 | $6.55M | Buy |
190,210
+4,966
| +3% | +$171K | ﹤0.01% | 3383 |
|
|
2021
Q4 | $8.12M | Buy |
185,244
+112,689
| +155% | +$4.94M | ﹤0.01% | 3166 |
|
|
2021
Q3 | $3.68M | Buy |
72,555
+43,718
| +152% | +$2.22M | ﹤0.01% | 4042 |
|
|
2021
Q2 | $1.5M | Buy |
28,837
+19,802
| +219% | +$1.03M | ﹤0.01% | 4840 |
|
|
2021
Q1 | $413K | Buy |
9,035
+8,929
| +8,424% | +$408K | ﹤0.01% | 5261 |
|
|
2020
Q4 | $5K | Buy |
+106
| New | +$5K | ﹤0.01% | 6769 |
|